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areas raises the specter of delayed oncogenesis in
neighboring soft tissue and has been implicated in the
constriction of vessels at the margins of irradiated
stents — the so-called “candy wrapper” or “edge”
effect. These issues must be resolved with carefully
crafted clinical trials, the results of which could jus-
tify the evidence-based expansion of indications for
a promising therapy for coronary and other vascular
disease. Nevertheless, at this time, brachytherapy ap-
pears to provide a valuable addition to the armamen-
tarium of the interventional cardiologist.
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ALARIA caused by 
 
Plasmodium falciparum,
 
 a
protozoan parasite of the blood, is responsible
for up to 2.7 million deaths yearly, mainly in children
in sub-Saharan Africa. Worldwide there are over 300
million new cases of malaria per year. Given the lack
of a suitable vaccine, the main ways to reduce morbid-
ity and mortality are the use of insecticide-impreg-
nated netting around the bed and chemoprophylaxis
for specific groups at increased risk, such as nonim-
mune travelers to an area where malaria is endemic,
pregnant women,1 and children with sickle cell ane-
mia. However, in many areas the effectiveness of treat-
ment and of efforts to prevent falciparum malaria is
being limited by the development of drug-resistant
strains.2
Chloroquine was introduced in the 1940s and soon
became the mainstay of therapy and prevention, be-
M
cause it was cheap and nontoxic and malaria para-
sites were universally susceptible to it. Resistance de-
veloped in Southeast Asia and South America at the
end of the 1950s and in Africa by the late 1970s. In
spite of its reduced efficacy, chloroquine is still the
first-line antimalarial drug in most parts of Africa, both
for reasons of cost and because of the widespread prev-
alence of partial immunity among symptomatic older
children and adults, a factor that enhances the effects
of the drug. The rates of resistance are increasing and
are having a major effect on the efforts to control
the morbidity and mortality associated with P. falci-
parum malaria. In Senegal, the emergence of chloro-
quine resistance over a 12-year period was associated
with at least a doubling of the risk of death from ma-
laria in children younger than 10 years of age.3 The
transmission of resistant strains can be facilitated by
unsuccessful treatment.4
Electron-microscopical analysis of malaria parasites
in red cells of mice and monkeys treated with chlor-
oquine shows that the parasite’s lysosome, where he-
moglobin is digested, is affected first. The link with
hemoglobin digestion explains the drug’s inactivity
against the pre-erythrocytic stage of the parasite in the
liver. Ferriprotoporphyrin IX, which is detached from
globin during digestion, is normally detoxified in the
parasite’s lysosome. The weak base chloroquine accu-
mulates in the acidic lysosome5 and binds to ferripro-
toporphyrin IX,6 thereby preventing its detoxification
and thus destroying the parasite (Fig. 1). Resistance
to chloroquine was shown to be due to reduced up-
take of the drug by the infected erythrocyte7 and pre-
sumably reflects a reduction in the accumulation of the
drug in the parasite’s lysosome. The slow rate of devel-
opment of resistance to chloroquine may reflect the
host-derived nature of the target, the importance of
hemoglobin digestion, and the complex mechanisms
required for resistance.
The ability of verapamil, when given in combina-
tion with chloroquine, to reverse in part the resist-
ance of strains in vitro parallels the ability of the drug
to inhibit multidrug resistance in cancer cells.8 There
are associations between chloroquine resistance and
mutations in an mdr-like gene (pfmdr 1) on chromo-
some 5 that encodes a protein, Pgh1, located in the
lysosomal membrane of the parasite.9 Field studies
showed that in areas with a high prevalence of resist-
ant strains, these mutant alleles could also be found
in chloroquine-sensitive parasites and were absent in
some resistant strains. Evidence of the involvement of
another genetic determinant was found in the proge-
ny of a genetic cross between chloroquine-resistant
and chloroquine-sensitive clones, the study of which
indicated a link between chloroquine resistance and
a locus on chromosome 7.10 Because both parental
clones had mutations in pfmdr 1, no primary link to
chromosome 5 could be demonstrated, but its in-
volvement could also not be ruled out.
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The results of extensive laboratory investigations of
pfcrt, a gene on chromosome 7 that encodes a trans-
membrane protein, PfCRT, in the lysosomal mem-
brane, have now been reported.11 The wild-type
PfCRT resembles proteins that facilitate the trans-
port of organic cations and may normally result in
the efflux of protonated basic amino acids,12 which
otherwise would accumulate in the lysosome. A mu-
tation in pfcrt leads to the substitution of threonine
(T76) for lysine (K76) at position 76 (K76T) and re-
sults in resistance to chloroquine in vitro. Alterations
in PfCRT could well reduce the efficiency of amino
acid export, and this change could account for the
lower pH in the lysosomes of chloroquine-resistant
parasites.11 Transfection of wild-type pfmdr 1 makes
mammalian lysosomes more acidic,13 and the pres-
ence of mutant Pgh1 might allow lysosomal pH to
reach a more normal level in a parasite with chloro-
quine resistance and a tendency to have a lower ly-
sosomal pH as a result of the mutation in pfcrt.
Figure 1. The Effect of Chloroquine on Heme Detoxification in the Lysosome of a Chloroquine-Sensitive Plasmodium falciparum
Malaria Parasite (Panel A) and a Chloroquine-Resistant Malaria Parasite (Panel B).
In Panel A, in the lysosome of a chloroquine-sensitive parasite, hydrogen ions enter through the proton pump, acidifying the lyso-
somal environment (pH 5.5). This process is probably regulated by the Pgh1 protein, which releases anions into the lysosome to
optimize the difference in the transmembrane charge. During the digestion of hemoglobin (Hb), protonated basic amino acids
(AAH+) are released together with toxic ferriprotoporphyrin IX (Fp9). Ferriprotoporphyrin IX is detoxified by polymerization to crys-
talline hemozoin. The weak base chloroquine, present in the cytoplasm (pH 7.4), dissolves in the lysosomal membrane and enters
the acidic environment, undergoing protonation to a form (CQH+) that is insoluble in the membrane and that quickly becomes con-
centrated. CQH+ binds to ferriprotoporphyrin IX and thus inhibits its polymerization, which leads to the accumulation of ferripro-
toporphyrin IX, causing membrane damage. The protonated basic amino acids exit the lysosome by means of the transmembrane
protein PfCRT. The PfCRT protein probably has a limited affinity for CQH+ and exports some of the drug from chloroquine-sensitive
parasites.
Panel B shows the lysosome of a parasite with mutations in pfcrt and pfmdr 1 related to chloroquine resistance. The mutant PfCRT
probably has an increased affinity for CQH+ and exports large amounts of the drug, enabling the polymerization of ferriprotopor-
phyrin IX to proceed normally. Concomitantly, the mutant PfCRT would have a reduced affinity for AAH+, which may reduce the
efficiency of the export of AAH+ and, in the absence of chloroquine, result in the accumulation of more protons (H+) in the lyso-
some. The presence of mutant Pgh1 may partially prevent this accumulation of protons, increasing the fitness of parasites with
pfcrt and pfmdr 1 mutations. The mutation in pfmdr 1 also increases the sensitivity of the parasite to mefloquine and artemisinin,
probably as a result of the partial inactivation of the ability of mutant Pgh1 to export these drugs.
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The association of mutations in pfcrt and pfmdr 1
with resistance in vivo is the subject of a field study
by Djimdé et al.14 whose results are reported in this
issue of the Journal. To assess the association between
clinical chloroquine resistance and mutations in these
genes, the investigators examined drug responses in
patients with uncomplicated falciparum malaria in an
area of Mali where the disease is endemic. The pos-
itive predictive value of pfcrt T76 (the percentage of
positive tests that correctly predicted a treatment fail-
ure) was only 30 percent, but the negative predictive
value (the percentage of negative tests that correctly
predicted successful treatment) was 98 percent. These
results improved appreciably when patients younger
than 10 years of age were considered as a separate
group. The positive predictive value should be high-
er in areas with a lower prevalence of endemic disease,
in epidemics, and in cases of malaria among travelers
to areas where the disease is endemic. Even in the area
that Djimdé et al. studied, the results showed that the
absence of pfcrt T76 was an excellent predictor of suc-
cessful chloroquine treatment.
The association of other mutations in pfcrt with
the clinical outcome is not as clear-cut as that be-
tween T76 and chloroquine treatment. It appears that
this one mutation, which leads to a change in a sin-
gle amino acid in a transmembrane domain, can pro-
vide a basal level of chloroquine resistance and may
be accompanied by additional compensatory muta-
tions. Enhanced levels of resistance may also require
the presence of a mutation in pfmdr 1. In West Af-
rican isolates, tyrosine at position 86 (Y86) is the mu-
tation of pfmdr 1 generally seen in association with
chloroquine resistance, so the absence of other muta-
tions in these samples is not unexpected. That pfmdr 1
has an ancillary role is emphasized by the observa-
tion that though Y86 was sometimes seen in the ab-
sence of pfcrt T76 in the samples obtained before
treatment, it was not seen alone in samples obtained
from patients in whom treatment was not successful.
Although the prevalence of pfcrt T76 in the sam-
ples obtained before treatment was only 41 percent,
the prevalence in samples obtained from patients with
persistent or recurrent infection after treatment (14
percent of the total study population) was 100 per-
cent. The respective values for pfmdr 1 Y86 were 50
percent and 86 percent, indicating selection for this
allele after chloroquine treatment, as reported earlier.15
In contrast to the results for pfcrt, 30 percent of the
samples obtained from patients with persistent or re-
current infection carried the wild-type allele at posi-
tion 86 of pfmdr 1, either alone (14 percent) or in
combination with the mutant allele (16 percent).
That the pfmdr 1 Y86 mutation is important is
shown by the increase in specificity (the percentage
of successful treatments that were correctly predicted
on the basis of a negative test) from 63 percent when
pfcrt T76 was considered alone to 78 percent when
pfcrt T76 and pfmdr 1 Y86 were considered together.
In laboratory transfections,16 the presence of mutant
pfmdr 1 enhanced resistance of clones only when there
was already a low level of chloroquine resistance (pre-
sumably these clones carried the pfcrt T76 allele).
These observations suggest that a mutation in pfcrt
is required to confer a basic level of resistance before
mutations in pfmdr 1 can have an effect. The presence
of both mutations may, however, be responsible for
the finding that in 13 percent of the resistant infec-
tions, the level of drug resistance was class II or III
(i.e., a level indicating persistent parasitemia). A rap-
id, sensitive test to detect pfcrt T76 in blood samples
may be useful in the treatment of infected patients,
since a negative result would indicate the probable ef-
fectiveness of treatment with chloroquine alone. Cost
considerations in many areas would support the use
of empirical treatment with chloroquine or another
alternative first-line drug, such as sulfadoxine–pyri-
methamine, in patients with uncomplicated malaria,
at least in adults. In the case of more expensive drug
regimens, the cost of the test would have to be bal-
anced against the potential saving in the costs of treat-
ment. Of more immediate value is the fact that screen-
ing an infected population for the presence of pfcrt
T76 could detect the arrival of resistance and, with
regular surveillance, could be used to monitor its prev-
alence. The results could help influence recommenda-
tions for the first-line treatment of malaria. Knowl-
edge of the initial mutation in chloroquine resistance
also has major implications for the design of rational
alternatives to the widely used 4-aminoquinolines.
DAVID C. WARHURST, D.SC., F.R.C.PATH.
London School of Hygiene and Tropical Medicine
London WC1E 7HT, United Kingdom
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PREDICTING CEREBRAL EDEMA 
DURING DIABETIC KETOACIDOSIS
EREBRAL edema is a devastating complication
of diabetic ketoacidosis and remains the leading
cause of serious illness and death in children with
diabetes mellitus.1 The causes of cerebral edema are
unknown, largely because of the lack of large-scale
population-based studies. However, several hypoth-
eses relating to possible antecedent risk factors and
the effects of various treatment regimens have been
proposed.1
In this issue of the Journal, Glaser et al.2 report
the results of a retrospective analysis of cases of chil-
dren with diabetic ketoacidosis at 10 centers. Among
6977 such children, the authors identified 61 with
cerebral edema. The incidence of cerebral edema was
0.9 percent, a rate remarkably similar to that reported
historically in the United States3 and recently in the
United Kingdom.4 As in previous studies, the risk was
highest among younger children with newly diag-
nosed diabetes.1 The 21 percent mortality rate asso-
ciated with cerebral edema was similar to that in the
United Kingdom,4 as was the morbidity rate, with a
substantial 27 percent of the survivors having neu-
rologic sequelae.
The development of cerebral edema may be the
result of the treatment that children receive for dia-
betic ketoacidosis; treatments such as high doses of in-
sulin and the administration of bicarbonate or large
volumes of hypotonic fluid would be the major cul-
prits.1 However, it is also possible that the condition
is an idiosyncratic response to diabetic ketoacidosis.
Thus far, no adequate proof for either hypothesis has
been advanced.
The study by Glaser et al. confirms previous re-
ports that cerebral edema can become evident even
before treatment for diabetic ketoacidosis is initiated,
but usually it develops 4 to 12 hours later.1,2 The only
treatment association detected by the authors was with
the administration of bicarbonate; other treatments
C
that previously have been implicated,1 such as a high
rate of fluid administration or the administration of
hypotonic fluid, were not associated with an increased
risk of cerebral edema. Nevertheless, a smaller increase
in the serum sodium concentration during therapy
was associated with cerebral edema, as suggested in
previous reports.1,5 However, as the authors state, the
failure of serum sodium concentrations to rise sub-
stantially could be a consequence, rather than a cause,
of cerebral edema.2
Glaser et al. are to be commended for their sys-
tematic study, but does it improve our understanding
of the pathophysiology of cerebral edema or provide
new guidelines for therapy? The authors note that
cerebral edema was associated with higher serum urea
nitrogen concentrations and lower partial pressures
of arterial carbon dioxide at the time of diagnosis;
they argue that this finding supports the hypothesis,
first proposed by Dillon et al.,6 that cerebral edema
is the result of reduced blood volume, aggravated by
a reduced partial pressure of arterial carbon dioxide
and leading to cerebral vasoconstriction, cerebral is-
chemia, and hypoxia. The reduced partial pressure of
arterial carbon dioxide at presentation in children with
cerebral edema may imply an increased respiratory
drive in response to acidosis. However, caution must
be used in interpreting blood pH values, partial pres-
sures of arterial carbon dioxide, and bicarbonate con-
centrations when corrections have been made to ac-
count for the collection of both arterial and venous
blood samples. Furthermore, whereas rapid reductions
in the partial pressure of arterial carbon dioxide may
lead to acute vasoconstriction, this process is often
reversed when low partial pressures are chronic, as in
cases of adaptation to metabolic acidosis. However, the
hypoxia theory has received support from those who
have suggested that bicarbonate therapy might reduce
the partial pressure of oxygen in the cerebrospinal flu-
id, leading to vasoconstriction and further brain hy-
poxia.7
The higher initial serum urea nitrogen concentra-
tions noted by Glaser et al. in children in whom cer-
ebral edema developed (and, by inference, the greater
degrees of renal insufficiency in these children) have
been linked to pure anion-gap acidosis, rather than
hyperchloremic acidosis.8 The type of acidosis may
therefore be important in predicting cerebral edema,
since regulation of cell volume by the sodium–hydro-
gen ion exchanger may be compromised by severe ac-
idosis.9 The higher serum urea nitrogen concentrations
in these children may reflect the chronic nature of di-
abetic ketoacidosis, because a long duration of symp-
toms has previously been associated with development
of cerebral edema.3
The data presented by Glaser et al. confirm previ-
ous reports that the administration of bicarbonate may
be a risk factor for cerebral edema in children with
diabetic ketoacidosis; however, over the past 10 years,
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